Combination of lemzoparlimab and HER2-ADC elicits enhanced activity against HER2 expressing tumors

  • Lemzoparlimab is a differentiated anti-CD47 antibody with novel epitope and RBC sparing properties.
  • CD47 is highly expressed on HER2-expressing tumor cells and dual blockade of CD47 and HER2 pathway was reported to increase the tumor growth inhibition in vitro and in vivo.
  • HER2-ADC induced immunogenic cell death of multiple cell lines, providing the scientific rationale to combine with CD47 antibody through the increased surface expression of CD47 and calreticulin.
  • Here we evaluated anti-tumor activity of lemzoparlimab in combination with HER2 ADC in cell derived xenograft (CDX) and patient derived xenograft (PDX) breast and gastric cancer models.